NeurAegis is a preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders including traumatic brain injury (TBI) and epilepsy. Founded in 2016, our initial focus is developing first-in-class, novel protease inhibitors for TBI where there are currently no FDA approved treatments.
For more information, follow us on LinkedIn.
NeurAegis Scientific Founder Michel Baudry Awarded $3.8M Grant from the Department of Defense to Advance Product Candidate for Treating Traumatic Brain Injury and Concussion
NeurAegis is led by a team with deep, relevant experience for developing novel therapeutics.
Michel Baudry, PhD
Chief Scientific Advisor
Joe Blanchard, MBA
President and Chief Executive Officer
Francesco Salituro, PhD
Preclinical Drug Development